Cluster 10 · Outcomes and use cases

What does psilocybin microdosing help with?

Twelve common reasons people ask about microdosing, separated by evidence type. Controlled microdosing findings remain limited and mixed; full-dose clinical research is labeled separately and is not treated as proof for repeated low doses.

90-second quick read · deeper research available

Need the full research version?

This is the 90-second quick-reference version on imicrodosing.net. For the cited deep dive, continue to the full .org research page.

Read the full .org research companion →Browse related 90-second reads →
Controlled microdose: mixed or nullObservational: association onlyFull-dose research: separateInsufficient condition-specific evidence

12 use cases — rated by evidence

Mixed
AnxietyMicrodosing evidenceObservational reports; placebo-controlled findings do not establish treatment.Read the evidence →
Mixed
DepressionMicrodosing evidenceFull-dose trials are separate; microdosing findings remain mixed.Read the evidence →
Insufficient
ADHD & focusMicrodosing evidenceNo established ADHD treatment or reliable cognitive-enhancement effect.Read the evidence →
Insufficient
AddictionMicrodosing evidenceFull-dose clinical studies do not validate a microdosing protocol.Read the evidence →
Insufficient
Chronic painMicrodosing evidenceNo established chronic-pain treatment effect from microdosing.Read the evidence →
Insufficient
Cluster headachesMicrodosing evidenceReports and small studies do not establish a universal protocol.Read the evidence →
Mixed
CreativityMicrodosing evidenceControlled work does not show a dependable creativity benefit.Read the evidence →
Full-dose only
End-of-life distressMicrodosing evidenceThe clinical evidence uses supervised perceptible doses, not microdosing.Read the evidence →
Insufficient
Sleep & insomniaMicrodosing evidenceNo established insomnia treatment; reported sleep effects vary.Read the evidence →
Insufficient
OCDMicrodosing evidenceNo established microdosing treatment evidence.Read the evidence →
Insufficient
PTSDMicrodosing evidenceMDMA research is a different substance and does not prove psilocybin microdosing.Read the evidence →
Mixed
Stress & burnoutMicrodosing evidenceSelf-reports exist; controlled condition-specific evidence is insufficient.Read the evidence →

Before you interpret a claim

Common questions

Q · 01

Which condition has proven microdosing benefits?

None has a sufficiently established condition-specific evidence base to support a universal treatment claim.

Q · 02

How long before an effect should appear?

No universal response timeline has been established. Expectation, unblinding, natural symptom change, and product variation can influence tracking.

Q · 03

Can full-dose trials be used as microdosing proof?

No. Dose, screening, psychological support, setting, and product standardization are materially different.

Product-format context

For product-format context, see the iMicrodosing.com products and client support.

View products & support →